Analysts’ Recent Ratings Updates for CareDx (CDNA)

A number of research firms have changed their ratings and price targets for CareDx (NASDAQ: CDNA):

• 12/29/2025 – CareDx had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – CareDx had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/21/2025 – CareDx was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 12/15/2025 – CareDx had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – CareDx had its price target raised by analysts at Wells Fargo & Company from $14.00 to $18.00. They now have an “equal weight” rating on the stock.
• 12/13/2025 – CareDx was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/8/2025 – CareDx had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – CareDx had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – CareDx had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – CareDx had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/18/2025 – CareDx was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating.
• 11/13/2025 – CareDx had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/8/2025 – CareDx was upgraded by analysts at Wall Street Zen from a “sell” rating to a “buy” rating.
• 11/7/2025 – CareDx was upgraded by analysts at Weiss Ratings from a “sell (d+)” rating to a “hold (c-)” rating.
• 11/6/2025 – CareDx had its price target raised by analysts at BTIG Research from $22.00 to $25.00. They now have a “buy” rating on the stock.

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.